HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy.

AbstractUNLABELLED:
Small-molecule drug combination therapies are an attractive approach to enhancing cancer chemotherapeutic responses. Therefore, this study aimed to investigate the potential of axitinib (AXT) and celastrol (CST) in targeting angiogenesis and mitochondrial-based apoptosis in cancer. Therefore, we prepared AXT/CST-loaded combination nanoparticles (ACML) with CST loaded in the mesoporous silica nanoparticles (MSN) and AXT in PEGylated lipidic bilayers. We showed that ACML effectively inhibited angiogenesis and mitochondrial function and was efficiently internalized in SCC-7, BT-474, and SH-SY5Y cells. Furthermore, hypoxia-inducible factor (HIF)-1α expression, which increased under hypoxic conditions in all cell lines exposed to ACML, markedly decreased, which may be critical for tumor inhibition. Western blotting showed the superior anticancer effect of combination nanoparticles in different cancer cells. Compared to the cocktail (AXT/CST), ACML induced synergistic cancer cell apoptosis. The AXT/CST-based combination nanoparticle synergism might be mediated by AXT, which controls vascular endothelial growth factor receptors while CST acts on target cell mitochondria. Importantly, ACML-treated mice showed remarkably higher tumor inhibition (64%) than other groups did in tumor xenograft models. Tumor xenograft immunohistochemistry revealed elevated caspase-3 and poly (ADP-ribose) polymerase and reduced CD31 and Ki-67 expression, clearly suggesting tumor apoptosis through mitochondrial and antiangiogenic effects. Overall, our results indicate that ACML potentially inhibited cell proliferation and induced apoptosis by blocking mitochondrial function, leading to enhanced antitumor efficacy.
STATEMENT OF SIGNIFICANCE:
In this research, we formulated an anticancer drug combination nanoparticle loaded with axitinib (AXT) in the lipidic bilayer of PEGylated liposomes and celastrol (CST) in mesoporous silica nanoparticles. The anticancer effects of the AXT/CST-loaded combination nanoparticle (ACML) were synergistic and superior to the other formulations and involved more efficient drug delivery to the tumor site with enhanced effects on angiogenesis and mitochondrial function. Therefore, our study demonstrated that the inhibition of cell proliferation and induction of apoptosis by ACML, which was mediated by blockade of mitochondrial function and anti-angiogenesis, led to enhanced antitumor efficacy, which may be potentially useful in the clinical treatment of cancer.
AuthorsJu Yeon Choi, Thiruganesh Ramasamy, Sung Yub Kim, Jeonghwan Kim, Sae Kwang Ku, Yu Seok Youn, Jae-Ryong Kim, Jee-Heon Jeong, Han-Gon Choi, Chul Soon Yong, Jong Oh Kim
JournalActa biomaterialia (Acta Biomater) Vol. 39 Pg. 94-105 (07 15 2016) ISSN: 1878-7568 [Electronic] England
PMID27163403 (Publication Type: Journal Article)
CopyrightCopyright © 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
Chemical References
  • Imidazoles
  • Indazoles
  • Lipid Bilayers
  • Pentacyclic Triterpenes
  • Triterpenes
  • Silicon Dioxide
  • Axitinib
  • celastrol
Topics
  • Animals
  • Axitinib
  • Cell Line, Tumor
  • Drug Delivery Systems (methods)
  • Drug Screening Assays, Antitumor
  • Female
  • Imidazoles (chemistry, pharmacokinetics, pharmacology)
  • Indazoles (chemistry, pharmacokinetics, pharmacology)
  • Lipid Bilayers (chemistry, pharmacokinetics, pharmacology)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Nanoparticles (chemistry, therapeutic use)
  • Neoplasms, Experimental (drug therapy, metabolism, pathology)
  • Pentacyclic Triterpenes
  • Porosity
  • Silicon Dioxide (chemistry, pharmacokinetics, pharmacology)
  • Triterpenes (chemistry, pharmacokinetics, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: